BCM
IONS icon

Bienville Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bienville Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,268
Closed -$210K – 144
2019
Q2 		$210K Buy
3,268
+204
+7% +$14.4K 0.03% 194
2019
Q1 		$249K Buy
+3,064
New +$198K 0.03% 147

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bienville Capital Management's IONS Position: Q3 2019 in Review

Bienville Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 3,268 shares — an estimated $210K sold.

Bienville Capital Management first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $249K in Q1 2019. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

  • Bienville Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Bienville Capital Management sold 3,268 Ionis Pharmaceuticals shares in Q3 2019, an estimated $210K.
  • Bienville Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Bienville Capital Management's Ionis Pharmaceuticals position peaked at $249K in Q1 2019.
  • 369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Bienville Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.